Stay updated on SAGE-217 Safety in MDD Insomnia Clinical Trial
Sign up to get notified when there's something new on the SAGE-217 Safety in MDD Insomnia Clinical Trial page.

Latest updates to the SAGE-217 Safety in MDD Insomnia Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2; no changes to study content, locations, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedRevision label updated from Revision: v3.2.0 to Revision: v3.3.1 on the page footer; otherwise study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check29 days agoChange DetectedA funding/operating-status notice was removed from the page. This change eliminates a general operational update and does not alter the study details or eligibility.SummaryDifference0.3%

- Check43 days agoChange DetectedThe sponsor of the study changed from Sage Therapeutics to Biogen, and Biogen is now listed as the sponsor and responsible party. Related sections such as the official title and sponsor information reflect Biogen’s involvement.SummaryDifference0.4%

- Check71 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference2%

- Check79 days agoChange DetectedAdded a new version tag (v3.1.0) and removed several drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the page.SummaryDifference0.2%

Stay in the know with updates to SAGE-217 Safety in MDD Insomnia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-217 Safety in MDD Insomnia Clinical Trial page.